液基细胞学和高危人乳头瘤状病毒DNA检测对宫颈病变筛查的价值

目的探讨液基细胞学（TCT）和高危人乳头瘤状病毒DNA（HR-HPV DNA）检测对宫颈病变筛查的价值。方法对南昌大学第二附属医院妇科门诊1682例宫颈炎患者进行TCT检查,并对其中TCT检查结果异常的患者行HR-HPV DNA检测。结果1682例患者TCT检查结果异常者158例,占9.39%,其中不典型鳞状细胞和腺细胞病变（ASC-US）63例（3.75%）,低度鳞状上皮内病变（LSIL）44例（2.61%）,高度鳞状上皮内病变（HSIL）45例（2.67%）,鳞状上皮细胞癌（SCC）6例（0.36%）。158例TCT检查异常者HR-HPV DNA检测阳性85例,阳性率53.78%;HR-HPV DNA阳性率分布为：ASC-US23.81%（15/63）、LSIL65.90%（29/44）、HSIL77.77%（35/45）、SCC100.00%（6/6）,阳性率随宫颈病变级别升高而升高。结论TCT和HR-HPV DNA检查是筛查宫颈癌前病变的有效方法,二者结合有利于提高宫颈癌及癌前病变的检出率。

The Value of Thinprep Cytologic Test and High-risk HPV DNA Testing on Screening for Cervical Lesions

Objective To explore the value of thinprep cytologic test（TCT）and high-risk hu- man papillomavirus DNA （HR-HPV DNA） detection of cervical disease screening. Methods Of the second affiliated hospital of nanchang university, 1 682 cases of out-patient gynecological patients with cervicitis TCT inspection, and one of TCT in patients with abnornal test abnormal test results for HR-HPV DNA testing. Results In the 1 682 patients,158 cases showed abnormal results for TCT,accounting for 9.39% ,ASC-US 63 cases （3.75%） ,LSIL 44 cases （9.61%） ,HSIL 45 cases （2.67%）, SCC 6 cases （0. 36 percent）. In 158 patients with abnormal cytology, there were 85 showing HR-HPV DNA testing positive,the positive rate was 53.78%, HR-HPV DNA positive rate for distribution：ASC-US 23.81% （15/63）,LSIL 65.90 % （29/44）, HSIL 77.77% （35/45） ,SCC 100.00%（6/6）. HR-HPV DNA positive rate of cervical lesions with high-level and higher. Conclusion TCT and HR-HPV DNA screening for cervical cancer screening may be an effective way to precancerous lesions, the combination will help improve cervical cancer and precancerous lesion detection rate.